Product Code: SR112025A5744
The global cord blood banking services market size was valued at USD 2.02 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 4.57 Billion by 2033, exhibiting a CAGR of 9.02% during 2025-2033. North America currently dominates the market, holding a significant market share of over 33.8% in 2024. The market is growing due to rising awareness about stem cell therapies, increasing prevalence of genetic disorders, advancements in regenerative medicine, government initiatives, and growing adoption of private banking. Moreover, the improved storage technologies, rising healthcare expenditure, expanding research applications, and increasing childbirth rates in key regions are some of the other factors fueling the cord blood banking services market share.
Cord blood banking is a procedure of collecting and storing life-saving stem cells from the umbilical cord and placenta for future use. It uses hematopoietic stem cells that are present in the cord blood of the baby to develop it into red blood cells (RBCs), white blood cells (WBCs) and platelets. It aids in the treatment of cancer, blood diseases and immune system disorders as cord blood banking is less complicated, painful and risky for the donor compared to the collection of stem cells from bone marrow. As a result, it finds extensive applications in hospitals, research institutes, and specialty clinics.
Cord Blood Banking Services Market Trends:
The growing prevalence of different cancers, such as lymphoma and leukemia, due to longer working hours, stressful lives, and excessive smoking and alcohol consumption represents one of the key factors driving the market. Moreover, there is an increase in the utilization of cord blood banking services for the treatment of immunodeficiency disorders across the globe. This, coupled with the increasing awareness among individuals about the benefits and wide availability of cord blood banking service providers, is propelling the growth of the market. In addition, governments of several countries are extensively investing in research and development (R&D) activities to facilitate clinical trials of cord blood stem cells. In line with this, the growing number of patients with damaged bone marrow worldwide is positively influencing the market. Besides this, the rising diagnostic screening of cord blood in private centers as per guidelines and regulations of regulatory authorities is offering lucrative growth opportunities to industry investors. Additionally, the expanding healthcare industry is strengthening the growth of the market.
Key Market Segmentation:
Breakup by Component:
Breakup by Storage Services:
- Public Cord Blood Banks
- Private Cord Blood Banks
Breakup by Application:
- Cancer Disease
- Diabetes
- Blood Disease
- Immune Disorders
- Metabolic Disorders
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Alphacord LLC, Americord Registry LLC, ATCC, California Cryobank, Cordlife Group LImited, Cryo-Cell International Inc., Global Cord Blood Corporation, LifeBank, LifeCell International Pvt. Ltd., National Cord Blood Program, Norton Healthcare Inc., Perkinelmer Inc. and StemCyte India Therapeutics Pvt. Ltd.
Key Questions Answered in This Report
- 1.How big is the cord blood banking services market?
- 2.What is the future outlook of the cord blood banking services market?
- 3.What are the key factors driving the cord blood banking services market?
- 4.Which region accounts for the largest cord blood banking services market share?
- 5.Which are the leading companies in the global cord blood banking services market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Cord Blood Banking Services Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Component
- 6.1 Cord Blood
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Cord Tissue
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Storage Services
- 7.1 Public Cord Blood Banks
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Private Cord Blood Banks
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
8 Market Breakup by Application
- 8.1 Cancer Disease
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Diabetes
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Blood Disease
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Immune Disorders
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
- 8.5 Metabolic Disorders
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
- 8.6 Others
- 8.6.1 Market Trends
- 8.6.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Alphacord LLC
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.2 Americord Registry LLC
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.3 ATCC
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.4 California Cryobank
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.5 Cordlife Group LImited
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.6 Cryo-Cell International Inc.
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.7 Global Cord Blood Corporation
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.8 LifeBank
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.9 LifeCell International Pvt. Ltd.
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.10 National Cord Blood Program
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.11 Norton Healthcare Inc.
- 14.3.11.1 Company Overview
- 14.3.11.2 Product Portfolio
- 14.3.12 Perkinelmer Inc.
- 14.3.12.1 Company Overview
- 14.3.12.2 Product Portfolio
- 14.3.12.3 Financials
- 14.3.12.4 SWOT Analysis
- 14.3.13 StemCyte India Therapeutics Pvt. Ltd.
- 14.3.13.1 Company Overview
- 14.3.13.2 Product Portfolio